<DOC>
	<DOCNO>NCT02303977</DOCNO>
	<brief_summary>The main purpose study see well combination Abraxane gemcitabine work people advanced adenocarcinoma NSCLC already treatment disease . Gemcitabine Abraxane FDA approve chemotherapy ; however , FDA approve combination treatment specific type cancer . Patients may continue receive study drug disease get bad unacceptable side effect .</brief_summary>
	<brief_title>Phase II Study Abraxane Gemicitabine Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologic cytologic diagnosis adenocarcinoma nonsmall cell lung cancer Stage IV nonsmall cell lung cancer recurrent disease approach curative intent . Firstline treatment standard platinum doublet chemotherapy regimen ( carboplatin cisplatin standard dose plus one follow drug standard dosing : paclitaxel , docetaxel , vinblastine , vinorelbine , pemetrexed , etoposide ) . Patients receive platinumbased chemotherapy localize lung cancer ( either adjuvant chemotherapy follow surgery chemotherapy give conjunction definitive radiation ) eligible cancer recur within 6 month platinumbased chemotherapy . Must recover toxic effect prior chemotherapy ECOG performance status 01 Life expectancy least 12 week Age 18 great Must measurable disease define least one lesion accurately measure least one dimension ( long diameter record &gt; 20 mm conventional technique &gt; 10 mm spiral CT scanning ) . Patients prior malignancy allow , provide treat curative intent evidence active disease . Patients must capable give informed consent willing able comply schedule visit , treatment plan laboratory testing . Bilirubin &lt; 1.5 mg/dL Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 2.5 X upper limit normal , unless bone metastasis present absence liver metastasis Patients must adequate bone marrow function : Platelets &gt; 100,000 cells/mm3 , Hemoglobin &gt; 9.0g/dL ANC &gt; 1,500 cells/mm3 Patients must adequate renal function : creatinine &lt; 1.5 mg/dL Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment Negative serum Î²hCG pregnancy test screening patient childbearing potential . Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) Patients EGFR EML4ALK mutation ECOG performance status &gt; 1 Patients previously treat gemcitabine Abraxane Uncontrolled intercurrent illness include , limited : uncontrolled ongoing infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Known HIV Hepatitis C Untreated central nervous system metastasis . Patients eligible clinically stable , steroids cranial irradiation ( whole brain radiation therapy , focal radiation therapy , stereotactic radio surgery ) end least 2 week prior enrollment , surgical resection perform least 2 week prior enrollment . Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy , investigational agent Pregnant breastfeeding patient , chemotherapy think present substantial risk fetus/infant . Men woman reproductive potential may participate study unless agree use effective contraceptive method study . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Patients must agree continue contraception 3 month date last study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>